Invivyd (IVVD) News Today $0.48 -0.01 (-2.98%) (As of 12:08 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Invivyd, Inc. (NASDAQ:IVVD) Director Sells 65,359 Shares of StockDecember 17 at 5:19 AM | insidertrades.comInvivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in StockInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 65,359 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $0.47, for a total value of $30,718.73. Following the sale, the director now directly owns 4,012,320 shares in the company, valued at approximately $1,885,790.40. The trade was a 1.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 16 at 10:20 PM | marketbeat.comFmr LLC Sells 1,046,775 Shares of Invivyd, Inc. (NASDAQ:IVVD)Fmr LLC decreased its stake in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 12.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,320,982 shares of the company's stock after selling 1,046December 13, 2024 | marketbeat.comTerrance Mcguire Sells 150,000 Shares of Invivyd, Inc. (NASDAQ:IVVD) StockDecember 12, 2024 | insidertrades.comInvivyd's (IVVD) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday.November 25, 2024 | marketbeat.comFY2024 Earnings Estimate for Invivyd Issued By HC WainwrightInvivyd, Inc. (NASDAQ:IVVD - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Invivyd in a report released on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.63) per share for the yNovember 22, 2024 | marketbeat.comInvivyd’s Resilient Strategy and Prospective Growth: Buy Rating Affirmed Amidst Pemgarda Setbacks and New Antibody DevelopmentsNovember 21, 2024 | markets.businessinsider.comInvivyd price target lowered to $3.55 from $9.50 at Morgan StanleyNovember 21, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for Invivyd (NASDAQ:IVVD) Stock PriceHC Wainwright decreased their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday.November 20, 2024 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in OctoberInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 8,270,000 shares, an increase of 15.8% from the October 15th total of 7,140,000 shares. Approximately 11.4% of the company's stock are sold short. Based on an average daily trading volume, of 463,300 shares, the days-to-cover ratio is currently 17.9 days.November 16, 2024 | marketbeat.comInvivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...November 16, 2024 | nz.finance.yahoo.comInvivyd’s Q3 2024: Revenue Growth and Strategic DevelopmentsNovember 16, 2024 | markets.businessinsider.comInvivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comEarnings Outlook For InvivydNovember 14, 2024 | benzinga.comInvivyd reports Q3 EPS (51c) vs (36c) last yearNovember 14, 2024 | markets.businessinsider.comInvivyd announces NEJM published letter to editor on PEMGARDANovember 14, 2024 | markets.businessinsider.comInvivyd, Inc. (IVVD) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comInvivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comInvivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the EditorNovember 14, 2024 | globenewswire.comInvivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, RespectivelyNovember 12, 2024 | globenewswire.comInvivyd (IVVD) Scheduled to Post Quarterly Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comInvivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comInvivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024November 6, 2024 | globenewswire.comInvivyd (NASDAQ:IVVD) Raised to Strong-Buy at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a research report on Wednesday.November 1, 2024 | marketbeat.comEF Hutton Initiates Coverage of Invivyd (IVVD) with Buy RecommendationOctober 31, 2024 | msn.comInvivyd’s PEMGARDA Shows Promising Phase 3 Results and Strong Market Potential Amidst FDA ClarificationOctober 30, 2024 | markets.businessinsider.comInvivyd reports preliminary Q3 PEMGARDA product revenue $9.3MOctober 29, 2024 | markets.businessinsider.comInvivyd announces 12-month exploratory data from CANOPY Phase 3 trialOctober 29, 2024 | markets.businessinsider.comInvivyd (NASDAQ:IVVD) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Invivyd in a report on Tuesday.October 29, 2024 | marketbeat.comInvivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term ProfitabilityOctober 29, 2024 | globenewswire.comInvivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent ParticipantsOctober 29, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest Down 8.0% in SeptemberInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 6,810,000 shares, a decrease of 8.0% from the September 15th total of 7,400,000 shares. Approximately 9.4% of the shares of the stock are sold short. Based on an average trading volume of 438,400 shares, the days-to-cover ratio is presently 15.5 days.October 16, 2024 | marketbeat.comInvivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024October 16, 2024 | globenewswire.comInvivyd (NASDAQ:IVVD) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comInvivyd Announces U.S. FDA Has Updated the PEMGARDA(TM) EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataOctober 1, 2024 | stockhouse.comInvivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataOctober 1, 2024 | globenewswire.comDuquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD)Duquesne Family Office LLC acquired a new position in Invivyd, Inc. (NASDAQ:IVVD - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 571,425 shares of the company's stock, valued at approximately $629,000. Duquesne FamilSeptember 26, 2024 | marketbeat.comBuy Rating Affirmed for Invivyd on Pemgarda’s Efficacy and Promising Revenue ProjectionsSeptember 25, 2024 | markets.businessinsider.comInvivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)September 23, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Stock Holdings Lifted by Acadian Asset Management LLCAcadian Asset Management LLC increased its holdings in Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 232.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 678,706 shares of the company's stock after buying an additional 474,301 shares during the period. AcadSeptember 18, 2024 | marketbeat.comInvivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19September 12, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd: Strong Product Performance and Strategic Market InitiativesSeptember 9, 2024 | markets.businessinsider.comInvivyd to Participate in Upcoming Investor ConferencesSeptember 5, 2024 | globenewswire.comInvivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™September 4, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd Amid Strong Potential of PEMGARDA Antibody for COVID-19 VariantsSeptember 3, 2024 | markets.businessinsider.comInvivyd's (IVVD) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Invivyd in a research report on Tuesday.September 3, 2024 | marketbeat.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestSeptember 3, 2024 | globenewswire.comBuy Rating on Invivyd Backed by Strong Phase 3 Data and Market CatalystsAugust 29, 2024 | markets.businessinsider.comInvivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of PemivibartAugust 27, 2024 | markets.businessinsider.comInvivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical TrialAugust 27, 2024 | globenewswire.com Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now IVVD Media Mentions By Week IVVD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVVD News Sentiment▼0.330.59▲Average Medical News Sentiment IVVD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVVD Articles This Week▼72▲IVVD Articles Average Week Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DMAC News Today ZNTL News Today FATE News Today TNYA News Today ATAI News Today ACRS News Today ACRV News Today SOPH News Today MOLN News Today LFVN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVVD) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
